Get the Stockscreener App
5.00
1.38%
-0.07
Alumis Inc stock is traded at $5.00, with a volume of 289.13K.
It is down -1.38% in the last 24 hours and up +15.47% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$5.07
Open:
$5.04
24h Volume:
289.13K
Relative Volume:
0.45
Market Cap:
$293.26M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.1865
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
-26.79%
1M Performance:
+15.47%
6M Performance:
-55.04%
1Y Performance:
+0.00%
1-Day Range:
$4.8518
$5.31
1-Week Range:
$4.8501
$7.3774
52-Week Range:
$3.18
$13.50
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
5.00 | 293.26M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - MarketScreener
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday - Benzinga
3 Biopharmaceutical Stocks Bucking the Sell-Off - MarketBeat
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alumis: Biotech's Stock Gains >100% In A MonthBut Risk Of Failure Is High (NASDAQ:ALMS) - Seeking Alpha
Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
Alumis Reaches US$465m Market Cap Benefiting Insider Stock Buying - simplywall.st
Insider Buying: Alumis Independent Director Bought US$130k Of Shares - Yahoo
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - The Manila Times
Alumis and ACELYRIN announce definitive merger plan By Investing.com - Investing.com South Africa
Alumis and ACELYRIN announce definitive merger plan - Investing.com Australia
Major Biopharma Merger: Alumis and ACELYRIN Unite with $737M War Chest for Immune Disease Breakthroughs - Stock Titan
Simulations Plus Posts Better-Than-Expected Results, Joins Savers Value Village, MarketAxess Holdings And Other Big Stocks Moving Higher On Friday - Benzinga
Alumis Inc. CEO Martin Babler buys $100,732 in company stock By Investing.com - Investing.com Australia
Alumis Inc. director Alan Colowick buys $129,544 in stock By Investing.com - Investing.com Australia
Top Executives Make Bold Moves with Alumis Inc. Stock Purchases! - TipRanks
Alumis Inc. CEO Martin Babler buys $100,732 in company stock - Investing.com
Alumis Inc. director Alan Colowick buys $129,544 in stock - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders - The Malaysian Reserve
Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday - Benzinga
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Alumis Inc. (NASDAQ:ALMS) Stock Holdings Increased by Charles Schwab Investment Management Inc. - Defense World
Q2 Earnings Forecast for Alumis Issued By Leerink Partnrs - MarketBeat
Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera Biosimilars - insights.citeline.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders - The Malaysian Reserve
Last-minute suitor nearly upends Alumis, Acelyrin merger - The Business Journals
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – SLRN - Bluefield Daily Telegraph
Alumis and Kaken Pharma announce collaboration worth $140 M for dermatology treatment in Japan - BioSpectrum Asia
Alumis Inc. Reports 2024 Results and Strategic Merger - TipRanks
Strategic Partnerships and Financial Projections Bolster Buy Rating for Alumis Inc. - TipRanks
Alumis stock holds $15 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com South Africa
Alumis stock holds $15 target, Buy rating at H.C. Wainwright - Investing.com
Q1 Earnings Forecast for Alumis Issued By Leerink Partnrs - Defense World
Alumis sees uptick as Kaken locks Japan rights for dermatology asset - FirstWord Pharma
Alumis and Kaken Pharmaceutical Announce Collaboration and - GlobeNewswire
Alumis rises on licensing deal with Japan’s Kaken - MSN
Acelyrin Sees Stock Price Rise Amid Rights Plan - Los Angeles Business Journal
What's Going On With Alumis Shares Tuesday? - Benzinga
Alumis and Kaken sign agreement in Japan to develop ESK-001 - Yahoo
Cassava ends work on Alzheimer’s drug; Alumis gets $40M upfront from Kaken - Endpoints News
Alumis and Kaken sign agreement in Japan for ESK-001 - Pharmaceutical Technology
Sector Update: Health Care - MarketScreener
Alumis stock soars on Japan dermatology deal By Investing.com - Investing.com Philippines
Alumis stock soars on Japan dermatology deal - Investing.com India
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Alumis stock rises on Kaken licensing deal (ALMS:NASDAQ) - Seeking Alpha
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Colowick Alan | Director |
Apr 02 '25 |
Buy |
7.49 |
2,300 |
17,235 |
18,404 |
| Babler Martin | President, CEO and Chairman |
Apr 01 '25 |
Buy |
6.44 |
15,650 |
100,733 |
106,454 |
| Foresite Labs, LLC | 10% Owner |
Jul 01 '24 |
Buy |
16.00 |
2,500,000 |
40,000,000 |
5,584,889 |
| Foresite Capital Management V, | 10% Owner |
Jul 01 '24 |
Buy |
16.00 |
2,500,000 |
40,000,000 |
5,584,889 |
| Tananbaum James B. | Director |
Jul 01 '24 |
Buy |
16.00 |
2,500,000 |
40,000,000 |
5,584,889 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):